A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Olema Pharmaceuticals (OLMA) is back in focus after Roche's Phase 3 breast cancer trial for giredestrant missed its primary endpoint, a setback that coincided with a sharp 41% drop in Olema's share price. See our latest analysis for Olema Pharmaceuticals. That reaction has not been limited to a single session either. The 7 day share price return is negative 33.91% and the 30 day share price return is negative 36.20% at a last close of US$14.91. At the same time, the 1 year total shareholder return of about 2.4x and the 3 year total shareholder return of just under 3x show how sharp this pullback is compared with a longer period in which investors who stayed in the stock have still seen very large gains overall. If this kind of volatility has you looking beyond a single name, it could be a good moment to scan a broader set of breast cancer and oncology names through our focused list of 34 healthcare AI stocks as potential research ideas. So with Olema now at US$14.91, after a
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMABusiness Wire
- Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 3/11/26 - Form 144
- 3/10/26 - Form 144
- 3/9/26 - Form 144
- OLMA's page on the SEC website